vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $151.1M, roughly 1.2× STURM RUGER & CO INC). On growth, STURM RUGER & CO INC posted the faster year-over-year revenue change (3.6% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $12.3M). Over the past eight quarters, STURM RUGER & CO INC's revenue compounded faster (5.1% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
AVNS vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $151.1M |
| Net Profit | $-1.3M | — |
| Gross Margin | 47.5% | 17.8% |
| Operating Margin | 1.4% | 2.3% |
| Net Margin | -0.7% | — |
| Revenue YoY | 0.7% | 3.6% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $-0.02 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $151.1M | ||
| Q3 25 | $177.8M | $126.8M | ||
| Q2 25 | $175.0M | $132.5M | ||
| Q1 25 | $167.5M | $135.7M | ||
| Q4 24 | $179.6M | $145.8M | ||
| Q3 24 | $170.4M | $122.3M | ||
| Q2 24 | $171.7M | $130.8M | ||
| Q1 24 | $166.1M | $136.8M |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $1.6M | ||
| Q2 25 | $-76.8M | $-17.2M | ||
| Q1 25 | $6.6M | $7.8M | ||
| Q4 24 | $-397.3M | — | ||
| Q3 24 | $4.3M | $4.7M | ||
| Q2 24 | $1.8M | $8.3M | ||
| Q1 24 | $-900.0K | $7.1M |
| Q4 25 | 47.5% | 17.8% | ||
| Q3 25 | 48.4% | 15.1% | ||
| Q2 25 | 52.6% | 3.9% | ||
| Q1 25 | 53.6% | 22.0% | ||
| Q4 24 | 54.6% | 22.8% | ||
| Q3 24 | 54.5% | 18.5% | ||
| Q2 24 | 55.7% | 22.3% | ||
| Q1 24 | 57.1% | 21.5% |
| Q4 25 | 1.4% | 2.3% | ||
| Q3 25 | 0.1% | -2.7% | ||
| Q2 25 | -42.6% | -15.6% | ||
| Q1 25 | 6.1% | 6.2% | ||
| Q4 24 | -233.0% | 7.8% | ||
| Q3 24 | 7.0% | 3.1% | ||
| Q2 24 | 3.7% | 6.9% | ||
| Q1 24 | 2.4% | 5.5% |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | 1.2% | ||
| Q2 25 | -43.9% | -13.0% | ||
| Q1 25 | 3.9% | 5.7% | ||
| Q4 24 | -221.2% | — | ||
| Q3 24 | 2.5% | 3.9% | ||
| Q2 24 | 1.0% | 6.3% | ||
| Q1 24 | -0.5% | 5.2% |
| Q4 25 | $-0.02 | $0.22 | ||
| Q3 25 | $-0.03 | $0.10 | ||
| Q2 25 | $-1.66 | $-1.05 | ||
| Q1 25 | $0.14 | $0.46 | ||
| Q4 24 | $-8.64 | $0.62 | ||
| Q3 24 | $0.09 | $0.28 | ||
| Q2 24 | $0.04 | $0.47 | ||
| Q1 24 | $-0.02 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $92.5M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $283.8M |
| Total Assets | $1.1B | $342.0M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $92.5M | ||
| Q3 25 | $70.5M | $80.8M | ||
| Q2 25 | $90.3M | $101.4M | ||
| Q1 25 | $97.0M | $108.3M | ||
| Q4 24 | $107.7M | $105.5M | ||
| Q3 24 | $89.0M | $96.0M | ||
| Q2 24 | $92.2M | $105.6M | ||
| Q1 24 | $75.8M | $115.3M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $283.8M | ||
| Q3 25 | $778.0M | $279.6M | ||
| Q2 25 | $776.3M | $289.3M | ||
| Q1 25 | $839.4M | $321.5M | ||
| Q4 24 | $828.5M | $319.6M | ||
| Q3 24 | $1.2B | $314.9M | ||
| Q2 24 | $1.2B | $321.5M | ||
| Q1 24 | $1.2B | $332.0M |
| Q4 25 | $1.1B | $342.0M | ||
| Q3 25 | $1.1B | $342.3M | ||
| Q2 25 | $1.0B | $349.5M | ||
| Q1 25 | $1.1B | $379.0M | ||
| Q4 24 | $1.2B | $384.0M | ||
| Q3 24 | $1.7B | $373.5M | ||
| Q2 24 | $1.7B | $376.7M | ||
| Q1 24 | $1.7B | $385.0M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $15.5M |
| Free Cash FlowOCF − Capex | $21.3M | $12.3M |
| FCF MarginFCF / Revenue | 11.8% | 8.2% |
| Capex IntensityCapex / Revenue | 3.8% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $15.5M | ||
| Q3 25 | $14.0M | $12.9M | ||
| Q2 25 | $6.8M | $14.7M | ||
| Q1 25 | $25.7M | $11.1M | ||
| Q4 24 | $57.9M | $20.0M | ||
| Q3 24 | $23.0M | $9.4M | ||
| Q2 24 | $27.8M | $18.7M | ||
| Q1 24 | $-8.0M | $7.3M |
| Q4 25 | $21.3M | $12.3M | ||
| Q3 25 | $7.0M | $7.0M | ||
| Q2 25 | $-4.2M | $9.1M | ||
| Q1 25 | $19.0M | $10.0M | ||
| Q4 24 | $53.1M | $16.4M | ||
| Q3 24 | $20.0M | $2.6M | ||
| Q2 24 | $21.9M | $10.1M | ||
| Q1 24 | $-12.1M | $5.6M |
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 3.9% | 5.5% | ||
| Q2 25 | -2.4% | 6.9% | ||
| Q1 25 | 11.3% | 7.4% | ||
| Q4 24 | 29.6% | 11.2% | ||
| Q3 24 | 11.7% | 2.1% | ||
| Q2 24 | 12.8% | 7.7% | ||
| Q1 24 | -7.3% | 4.1% |
| Q4 25 | 3.8% | 2.1% | ||
| Q3 25 | 3.9% | 4.6% | ||
| Q2 25 | 6.3% | 4.2% | ||
| Q1 25 | 4.0% | 0.8% | ||
| Q4 24 | 2.7% | 2.5% | ||
| Q3 24 | 1.8% | 5.5% | ||
| Q2 24 | 3.4% | 6.6% | ||
| Q1 24 | 2.5% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 1.98× | ||
| Q2 24 | 15.44× | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
